Davide Frumento | Molecular Oncology | Best Researcher Award

Prof. Davide Frumento | Molecular Oncology | Best Researcher Award

Adjunct Professor, RomaTre University, Italy

Dr. Davide Frumento is an experienced academic and researcher currently serving as an adjunct professor at Roma Tre University and Milan University in Italy. With a strong background in chemical engineering and biotechnology, he has contributed extensively to the scientific community in various research fields. His multidisciplinary expertise bridges molecular oncology, epigenetics, and biotechnology. Passionate about advancing scientific knowledge, Dr. Frumento has worked in both academic and industry settings, collaborating with top-tier institutions like Harvard University. His research is focused on innovative solutions in health, biotechnology, and environmental sustainability.

Profile

Orcid

Education 

Dr. Davide Frumento holds a PhD in Chemical Engineering from Genoa University (2012-2015), where he specialized in biotechnology applications. He graduated with a BSc and MSc in Biotechnology from the same institution (2005-2011). He further broadened his qualifications with a certification as a Scientific Expert for Criminal Procedures Court of Savona (2024). His academic journey reflects a consistent commitment to advancing his knowledge and skills, particularly in molecular sciences. Throughout his career, Dr. Frumento has continuously expanded his expertise by engaging in postdoctoral research at prominent institutions, including the University of Genoa, Milan University, and Harvard University. His extensive education has laid a strong foundation for his contributions to both academia and the industry.

Experience

Dr. Frumento has a distinguished career in academia and research. Since February 2025, he has served as an adjunct professor at the Penitentiary University Center, Milan University. He also holds a position as an adjunct professor in Epigenetics at Roma Tre University, Italy, since 2021. Previously, he has worked as a postdoctoral researcher at Genoa University, San Raffaele Hospital, and Milan University, where he contributed to research in health sciences and biotechnology. His postdoctoral research has spanned multiple departments, including DISSAL, DIMES, and DIFAR, focusing on various aspects of molecular biology, microbiota, and immunology. Dr. Frumento’s industrial experience includes a role as a Quality Control Microbiology Analyst at Noberasco SpA, further showcasing his diverse professional background. His broad expertise in both academic and industry research makes him a significant contributor to the scientific community.

Awards and Honors

Dr. Frumento’s contributions to the scientific field have earned him several prestigious awards. Notably, in 2021, he received the Smart Cup Scientific Award for Innovation and Technology from Regione Liguria, recognizing his work in health and environmental technology implementation. Earlier, in 2014, he won the Start Cup Scientific Award from the University of Genoa for his innovative work on a microtubular photobioreactor, aimed at improving microalgae culture for commercial use. His dedication to scientific innovation is also reflected in his membership in multiple scientific and technical organizations, including STRA and the Research Data Alliance. Dr. Frumento’s recognition within both the academic and industry sectors highlights his commitment to advancing research in molecular sciences, biotechnology, and environmental sustainability.

Research Focus

Dr. Frumento’s research spans several cutting-edge areas of molecular biology, with particular emphasis on biotechnology, molecular oncology, epigenetics, and environmental sciences. His work on the human microbiota’s role in immune responses and diseases such as hepatitis C and multiple sclerosis has contributed significantly to understanding their interplay. Additionally, he has explored the role of sirtuins in autoimmunity, studying SIRT6 inhibition as a therapeutic strategy for multiple sclerosis and other autoimmune diseases. Dr. Frumento’s research in the application of light-based technologies in immunotherapy further highlights his focus on innovative solutions for health and disease management. His work extends to environmental sustainability, where he investigates biotechnological applications for waste management and bioengineering, particularly in areas such as microalgae culture. By blending molecular biology with practical applications in medicine and the environment, Dr. Frumento continues to push the boundaries of scientific discovery.

Publication Top Notes

  • Interaction Between Human Microbiota, Immune System, and Hepatitis C Virus Infection: A Narrative Review 🦠
  • Light-based technologies in immunotherapy: advances, mechanisms, and applications 💡
  • Effects of Wildfire Exposure on the Human Immune System 🔥🧬
  • Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment 💊
  • Health Technology Assessment (HTA) sull’introduzione di coorti aggiuntive per la vaccinazione contro il meningococco 🦠💉
  • Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration 🧠
  • E-Muser (Enhanced Multiple Sclerosis Expected Rate): A Technical Improvement 🧑‍🔬
  • Sarcoglycanopathies: A Novel Predictive Approach 🧬
  • SIRT6 inhibition as a therapeutic approach for treating multiple sclerosis 🧠💉
  • DAI (Disease Aggressiveness Index) Implementation 📊
  • MuSER (Multiple Sclerosis Expected Rate) Predictive Model Development 🧠📈
  • Gut Microbiota Role in Liver Regeneration 🦠💡
  • Microbiota and HCV Infection Interplay 🦠
  • Oral bacteria contribution in wine flavor perception 🍷🦠
  • The efficacy of the new anti HCV therapy, implementation of a path based on the logic of micro-elimination in the Department of Mental Health and Addictions ASL4 Chiavarese 💊

 

 

Bawinile Hadebe | Breast Cancer | Best Researcher Award

Dr. Bawinile Hadebe | Breast Cancer | Best Researcher Award

Head Clinical Unit, Inkosi Albert Luthuli Central Hospital, South Africa

Dr. Bawinile Pearl-Gene Hadebe is an esteemed Nuclear Medicine specialist, currently serving as the Head of the Nuclear Medicine Department at Inkosi Albert Luthuli Central Hospital in South Africa. She is also an Honorary Lecturer at the University of KwaZulu-Natal. Bawinile holds an MBChB from the University of Cape Town, with postgraduate qualifications in Nuclear Medicine, including the FCNP(SA) and an MMed. She is pursuing a PhD in Nuclear Medicine at the University of KwaZulu-Natal. With a focus on clinical research, her work has made significant contributions to molecular imaging in oncology, particularly in oropharyngeal squamous cell carcinoma. Bawinile is known for her leadership in training future nuclear medicine specialists and her global impact as a researcher. She has been recognized with numerous awards for her research excellence and academic achievements. Her interests include jogging, traveling, and reading.

Profile

Google Scholar

Education

Dr. Bawinile Pearl-Gene Hadebe completed her medical studies at the University of Cape Town, where she earned a Bachelor of Medicine and Bachelor of Surgery (MBChB) degree from 2002 to 2007. Her commitment to advancing her career in nuclear medicine led her to specialize in the field, and she became a Fellow of the College of Nuclear Physicians of South Africa (FCNP) in October 2015. She also holds a Master of Medicine (MMed) degree, where her research on 99mTc-MIBI scintimammography in breast cancer patients earned her significant recognition, with the abstract published in the World Journal of Nuclear Medicine. Currently, Bawinile is a PhD candidate at the University of KwaZulu-Natal, focusing on the clinical impact of 68Ga-Pentixafor in oropharyngeal squamous cell carcinoma, with a focus on HIV-infected and non-infected patients. Her academic journey has been marked by academic excellence and leadership.

Experience

Dr. Bawinile Pearl-Gene Hadebe has extensive experience in both clinical practice and academic leadership. She currently serves as the Head of the Nuclear Medicine Department at Inkosi Albert Luthuli Central Hospital, where she plays a critical role in patient care and medical education. Her past leadership roles include Acting Academic Head of Department at the University of KwaZulu-Natal’s Nuclear Medicine Department. Prior to these, she was a Specialist Nuclear Physician at Inkosi Albert Luthuli Central Hospital and Sefako Makgatho Health Sciences University. Dr. Hadebe’s experience spans both public and academic health institutions, with her expertise in nuclear medicine and imaging helping to shape the next generation of medical professionals. Additionally, she has worked at several hospitals, including Dr. George Mukhari Academic Hospital and Mmametlhake Community Hospital, contributing to a broad range of patient care and specialized research projects in nuclear medicine and oncology.

Awards and Honors

Dr. Bawinile Pearl-Gene Hadebe has received numerous prestigious awards and honors in recognition of her contributions to the field of nuclear medicine. In 2023, she was awarded the Discovery PhD Fellowship Award, a significant recognition for her ongoing research in molecular imaging and oncology. She also secured the SAMRC self-initiated research fund, providing R200,000 per year for three years (2023–2025) to advance her research. Her groundbreaking work on nuclear imaging techniques has earned her the Vulindlela Holdings research grant of R45,000 for her PhD research. Dr. Hadebe has also earned international accolades, winning the Best International Abstract Award for South Africa at the SNMMI meeting in Toronto (June 2024) and the Best Abstract Award at the iPET meeting in Vienna (October 2024). Her expertise has led to her selection as an international expert at the International Atomic Energy Agency (IAEA) regional training course in Cairo, Egypt, in August 2024.

Research Focus

Dr. Bawinile Pearl-Gene Hadebe’s research primarily focuses on the application of nuclear medicine and molecular imaging in oncology, specifically in the diagnosis and management of cancers such as oropharyngeal squamous cell carcinoma (SCC). Her PhD research explores the clinical impact of 68Ga-Pentixafor PET/CT in evaluating CXCR-4 expression in oropharyngeal SCC in both HIV-infected and non-infected patients. The aim is to assess the diagnostic performance of this molecular imaging technique in the context of KwaZulu-Natal’s unique healthcare challenges. In addition, her earlier work, such as the role of 99mTc-MIBI scintimammography in breast cancer diagnosis, has demonstrated the utility of nuclear medicine in improving the detection and management of malignancies. Dr. Hadebe’s research is not only scientifically significant but also highly relevant to addressing the healthcare needs in resource-constrained settings.

Publication Top Notes

  • Current Status of 68Ga-Pentixafor in Solid Tumours 🧬🩺
  • Molecular Imaging and Theranostics in Ovarian Cancer: The Role of Nuclear Medicine 🔬💉
  • The Clinical Utility of 2-deoxy-2-[18F] Fluoro-d-glucose Positron Emission Tomography in Guiding Myocardial Revascularisation 🫀📊
  • The Role of 99m Tc-Mibi Scintimammography in Predicting Malignancy in Patients Suspected to Have Fibroadenomas of the Breast on Mammography 🩻👩‍⚕️
  • Assessing the Diagnostic Accuracy of 99mTc-MIBI Scintimammography in Predicting Malignancy in Patients Suspected to Have Fibroadenomas of the Breast 🩻🔍

 

 

Yousif Kariri | Cancer | Best Researcher Award

Dr Yousif Kariri | Cancer | Best Researcher Award

Assistant Professor , Shaqra University , Saudi Arabia

Dr. Y.A. Kariri is a Saudi researcher and academic, currently an Assistant Professor at Shaqra University’s College of Applied Medical Sciences in Saudi Arabia. Born in Jazan on February 11, 1988, he has an extensive academic and professional background spanning multiple countries. He earned a BSc in Clinical Laboratory Science from King Khalid University, an MSc in Medical Laboratory Sciences from RMIT University (Australia), and a PhD in Pathology from the University of Nottingham (UK). Dr. Kariri has expertise in cancer research, particularly in breast cancer, and is an active member of multiple pathology societies. As the Head of Online Learning and Learning Resources at Shaqra University, he has demonstrated leadership in academic administration. He has been instrumental in driving scientific research initiatives and is also an expert in cell culture and data analysis. Dr. Kariri is passionate about integrating advanced research methodologies in education.

Profile

Strengths for the Award

  1. Advanced Educational Qualifications:
    • PhD in Pathology (University of Nottingham, UK, 2022) — This is a high-level qualification and highlights a solid foundation in scientific research.
    • Master’s and Bachelor’s Degrees — The individual has international experience, having studied in Australia and the UK, further enhancing their research capacity and global perspective.
  2. Relevant and Impactful Research Contributions:
    • Publications in High-Impact Journals:
      • The individual has contributed to several peer-reviewed journal articles in oncology, specifically breast cancer research, with multiple publications in reputable journals like Cancers, Breast Cancer Research and Treatment, and Pathobiology. These contributions are significant, especially the involvement in studies that examine molecular mechanisms of breast cancer and biomarkers in cancer prognosis.
      • Notable publications include research on gene expression, prognostic biomarkers, and lymphovascular invasion, areas critical to advancing cancer diagnostics and treatment.
      • Articles such as “Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer” demonstrate a deep engagement with molecular pathology.
  3. Leadership and Experience in Academia:
    • The individual has held multiple leadership roles at Shaqra University, including Head of Online Learning and Learning Resources and Head of Student Activities, demonstrating the ability to lead teams and enhance educational outcomes.
    • They have also served as an Assistant Professor and have experience in both teaching and curriculum development, particularly in clinical laboratory sciences.
  4. Interdisciplinary Expertise:
    • Expertise in cell culture (in vitro), data analysis (SPSS, PRISM, Cluster analysis), and experience as a medical technologist adds practical knowledge to the research profile, helping bridge the gap between laboratory work and applied medical sciences.
    • Involvement in the Scientific Research Committee and as a publication reviewer in cancer research journals showcases their ability to critically engage with current scientific work and contribute to advancing the field.
  5. International Exposure:
    • Having studied and worked in three different countries (Saudi Arabia, Australia, and the UK), this individual brings a broad, international perspective to their research and teaching, enhancing their academic and professional profile.

Areas for Improvement

  1. Broader Research Collaborations:
    • While the individual has excellent research experience, their publications appear to focus primarily on breast cancer. Exploring broader collaborations in other areas of oncology or interdisciplinary research could further enhance their visibility and impact in the scientific community.
    • Expanding collaborations with international research institutions or leading cancer centers could also broaden the scope and depth of their research, potentially leading to larger-scale, multicentric studies.
  2. Increased Research Grant Applications:
    • The individual’s profile does not mention securing significant research funding or grants. Applying for competitive research grants could enhance the individual’s research capacity and provide more opportunities for large-scale projects, particularly in the area of cancer research.
  3. Further Outreach and Public Engagement:
    • Engaging more with the public or policy-making bodies through science communication efforts, public lectures, or collaborations with healthcare professionals could raise awareness about their research and broaden its impact beyond academia.

Education 

Dr. Y.A. Kariri’s educational journey has been both diverse and international. He completed his BSc in Clinical Laboratory Science from King Khalid University (2011), laying the foundation for his career in laboratory sciences. He then pursued an MSc in Medical Laboratory Sciences from the Royal Melbourne Institute of Technology University (RMIT) in Australia (2017), where he honed his skills in molecular biology and pathology. To further his research aspirations, Dr. Kariri earned a PhD in Pathology from the University of Nottingham (UK) in 2022, where his research focused on the molecular mechanisms behind breast cancer and lymphovascular invasion. Alongside his formal education, Dr. Kariri participated in various professional development programs, including a Higher Education Developer Diploma from the University of Nottingham (2022), which enhanced his teaching and academic leadership skills.

Experience

Dr. Y.A. Kariri has a rich blend of academic and research experience. He began his professional journey with a one-year internship at King Fahad Hospital in Jazan (2010-2011), where he gained hands-on experience in clinical laboratory operations. He then pursued an MSc project at RMIT University, focusing on medical laboratory sciences (2017). Since joining Shaqra University in 2017, Dr. Kariri has taken on several significant roles, including Secretary of the Scientific Council (2017-2018). In 2022, he became an Assistant Professor at the College of Applied Medical Sciences, where he continues to teach and conduct research. He has also served as the Head of Online Learning and Learning Resources and Head of Students Activities at Shaqra University (2022–2024). In addition, Dr. Kariri is a member of the Scientific Research Committee and has extensive experience in cell culture and data analysis.

Awards and Honors

Dr. Y.A. Kariri has been the recipient of several prestigious awards and honors, recognizing his academic and research excellence. He was awarded the King Abdullah Scholarship Program (2008-2011) for his master’s degree, an honor that allowed him to pursue advanced studies at RMIT University in Australia. He was also a PhD Scholar from Shaqra University in Saudi Arabia, enabling his research on breast cancer molecular mechanisms. His international educational background and research contributions have earned him recognition within the academic community. As a researcher, he has been honored with invitations to serve as a publication reviewer for several high-impact journals focusing on oncology and pathology. His leadership roles at Shaqra University, particularly in advancing online learning and student activities, have further cemented his reputation as an influential educator and scholar.

Research Focus 

Dr. Y.A. Kariri’s research focuses primarily on breast cancer and its molecular mechanisms, with an emphasis on lymphovascular invasion (LVI) and related prognostic biomarkers. His PhD project at the University of Nottingham (UK) explored the molecular genes driving breast cancer and their role in LVI, a key factor in cancer metastasis and poor prognosis. His work has been instrumental in identifying and validating novel biomarkers and gene signatures that could serve as therapeutic targets and predictive indicators for cancer progression. His studies have contributed to the broader understanding of cancer cell migration, gene expression, and the molecular complexity of invasive cancer. Dr. Kariri is skilled in cell culture (in vitro) and advanced data analysis, using tools like SPSS, PRISM, and Cluster Analysis to extract meaningful insights from experimental data. His research continues to bridge the gap between molecular biology and clinical application in cancer therapy.

Publications

  1. The role of the ALKBH5 RNA demethylase in invasive breast cancer 🧬🔬
  2. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer 🔬📊
  3. Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer 🧪📑
  4. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer 💉📉
  5. The itim-containing receptor: Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) modulates immune response and confers poor prognosis in invasive breast carcinoma 🧫💥
  6. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer 🧬📈
  7. Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype 🔬🌱
  8. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer 🧬🔍
  9. Utility of ankyrin 3 as a prognostic marker in androgen-receptor‑positive breast cancer 🔬⚖️
  10. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer 🧪🧬

Conclusion

This individual is undoubtedly a strong candidate for the Best Researcher Award based on their extensive academic background, significant contributions to cancer research, and leadership in higher education. Their research has direct implications for cancer diagnostics, prognosis, and treatment, with a focus on the molecular mechanisms that drive breast cancer, making them highly relevant to current healthcare challenges.Their strengths in academic leadership, combined with their technical expertise in laboratory sciences, make them a well-rounded and capable researcher. However, expanding their research horizons, applying for larger research grants, and further increasing their public engagement could elevate their profile even further.